The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Apropovir     [(2R)-1-(6-aminopurin-9- yl)propan-2...

Synonyms: Tenefovir, Tenofovir, PMPA, D,L-Tenofovir, CHEMBL483, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Apropovir


Psychiatry related information on Apropovir


High impact information on Apropovir


Chemical compound and disease context of Apropovir


Biological context of Apropovir


Anatomical context of Apropovir


Associations of Apropovir with other chemical compounds


Gene context of Apropovir


Analytical, diagnostic and therapeutic context of Apropovir


  1. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Tsai, C.C., Follis, K.E., Sabo, A., Beck, T.W., Grant, R.F., Bischofberger, N., Benveniste, R.E., Black, R. Science (1995) [Pubmed]
  2. HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistance. Ren, J., Stammers, D.K. Trends Pharmacol. Sci. (2005) [Pubmed]
  3. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. De Clercq, E. Clin. Microbiol. Rev. (2003) [Pubmed]
  4. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1. Margot, N.A., Miller, M.D. Antivir. Ther. (Lond.) (2005) [Pubmed]
  5. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Lada, O., Benhamou, Y., Cahour, A., Katlama, C., Poynard, T., Thibault, V. Antivir. Ther. (Lond.) (2004) [Pubmed]
  6. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. Nelson, M.R., Katlama, C., Montaner, J.S., Cooper, D.A., Gazzard, B., Clotet, B., Lazzarin, A., Schewe, K., Lange, J., Wyatt, C., Curtis, S., Chen, S.S., Smith, S., Bischofberger, N., Rooney, J.F. AIDS (2007) [Pubmed]
  7. Tenofovir-containing nucleoside/nucleotide-only antiretroviral maintenance therapy: decision making and virological outcome. Buehlmann, M., Chave, J.P., Flepp, M., Schiffer, V., Keiser, O., Furrer, H. HIV clinical trials. (2006) [Pubmed]
  8. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. White, K.L., Chen, J.M., Feng, J.Y., Margot, N.A., Ly, J.K., Ray, A.S., Macarthur, H.L., McDermott, M.J., Swaminathan, S., Miller, M.D. Antivir. Ther. (Lond.) (2006) [Pubmed]
  9. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Borroto-Esoda, K., Vela, J.E., Myrick, F., Ray, A.S., Miller, M.D. Antivir. Ther. (Lond.) (2006) [Pubmed]
  10. Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy. Côté, H.C., Magil, A.B., Harris, M., Scarth, B.J., Gadawski, I., Wang, N., Yu, E., Yip, B., Zalunardo, N., Werb, R., Hogg, R., Harrigan, P.R., Montaner, J.S. Antivir. Ther. (Lond.) (2006) [Pubmed]
  11. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/tenofovir in highly active antiretroviral therapy experienced patients. Antinori, A., Trotta, M.P., Nastao, P., Bini, T., Bonora, S., Castagnas, A., Zaccarelli, M., Quirino, T., Landonio, S., Merli, S., Tozzi, V., Di Perri, G., Andreoni, M., Perno, C.F., Carosi, G. Antivir. Ther. (Lond.) (2006) [Pubmed]
  12. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases. Allavena, C., Le Moal, G., Michau, C., Chiffoleau, A., Raffi, F. Antivir. Ther. (Lond.) (2006) [Pubmed]
  13. A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine. Ross, L.L., Dretler, R., Gerondelis, P., Rouse, E.G., Lim, M.L., Lanier, E.R. AIDS (2006) [Pubmed]
  14. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. Margot, N.A., Isaacson, E., McGowan, I., Cheng, A.K., Schooley, R.T., Miller, M.D. AIDS (2002) [Pubmed]
  15. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. Domingo, P., Labarga, P., Palacios, R., Guerro, M.F., Terrón, J.A., Elías, M.J., Santos, J., Ruiz, M.I., Llibre, J.M. AIDS (2004) [Pubmed]
  16. Clinical trial results of new therapies for HBV: implications for treatment guidelines. Gish, R.G. Semin. Liver Dis. (2005) [Pubmed]
  17. The steady-state pharmacokinetics of nelfinavir in combination with tenofovir in HIV-infected patients. Kruse, G., Esser, S., Stocker, H., Breske, A., Koerber, A., Kopperman, M., Wiehler, H., Ross, B., Möcklinghoff, C., Hill, A., Becker, M., Kurowski, M. Antivir. Ther. (Lond.) (2005) [Pubmed]
  18. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. Núñez, M., Pérez-Olmeda, M., Díaz, B., Ríos, P., González-Lahoz, J., Soriano, V. AIDS (2002) [Pubmed]
  19. Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques. Magierowska, M., Bernardin, F., Garg, S., Staprans, S., Miller, M.D., Van Rompay, K.K., Delwart, E.L. J. Virol. (2004) [Pubmed]
  20. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice. Naesens, L., Bischofberger, N., Augustijns, P., Annaert, P., Van den Mooter, G., Arimilli, M.N., Kim, C.U., De Clercq, E. Antimicrob. Agents Chemother. (1998) [Pubmed]
  21. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. Barrios, A., Rendón, A., Negredo, E., Barreiro, P., Garcia-Benayas, T., Labarga, P., Santos, J., Domingo, P., Sánchez-Conde, M., Maida, I., Martín-Carbonero, L., Núñez, M., Blanco, F., Clotet, B., Sambeat, M.A., Gil, P., Gonzalez-Lahoz, J., Cooper, D., Soriano, V. AIDS (2005) [Pubmed]
  22. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. Ghosn, J., Chaix, M.L., Peytavin, G., Rey, E., Bresson, J.L., Goujard, C., Katlama, C., Viard, J.P., Tréluyer, J.M., Rouzioux, C. AIDS (2004) [Pubmed]
  23. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Birkus, G., Hitchcock, M.J., Cihlar, T. Antimicrob. Agents Chemother. (2002) [Pubmed]
  24. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Lee, W.A., He, G.X., Eisenberg, E., Cihlar, T., Swaminathan, S., Mulato, A., Cundy, K.C. Antimicrob. Agents Chemother. (2005) [Pubmed]
  25. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Podzamczer, D., Ferrer, E., Gatell, J.M., Niubo, J., Dalmau, D., Leon, A., Knobel, H., Polo, C., Iniguez, D., Ruiz, I. Antivir. Ther. (Lond.) (2005) [Pubmed]
  26. Hypokalemia in HIV patients on tenofovir. Cirino, C.M., Kan, V.L. AIDS (2006) [Pubmed]
  27. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. North, T.W., Van Rompay, K.K., Higgins, J., Matthews, T.B., Wadford, D.A., Pedersen, N.C., Schinazi, R.F. J. Virol. (2005) [Pubmed]
  28. Rapid viral decay in simian immunodeficiency virus-infected macaques receiving quadruple antiretroviral therapy. Brandin, E., Thorstensson, R., Bonhoeffer, S., Albert, J. J. Virol. (2006) [Pubmed]
  29. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. Schmutz, G., Nelson, M., Lutz, T., Sheldon, J., Bruno, R., von Boemmel, F., Hoffmann, C., Rockstroh, J., Stoehr, A., Wolf, E., Soriano, V., Berger, F., Berg, T., Carlebach, A., Schwarze-Zander, C., Schürmann, D., Jaeger, H., Mauss, S. AIDS (2006) [Pubmed]
  30. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Imaoka, T., Kusuhara, H., Adachi, M., Schuetz, J.D., Takeuchi, K., Sugiyama, Y. Mol. Pharmacol. (2007) [Pubmed]
  31. Renal Transport of Adefovir, Cidofovir, and Tenofovir by SLC22A Family Members (hOAT1, hOAT3, and hOCT2). Uwai, Y., Ida, H., Tsuji, Y., Katsura, T., Inui, K. Pharm. Res. (2007) [Pubmed]
  32. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Mallants, R., Van Oosterwyck, K., Van Vaeck, L., Mols, R., De Clercq, E., Augustijns, P. Xenobiotica (2005) [Pubmed]
  33. Macrophage activation by antiviral acyclic nucleoside phosphonates in dependence on priming immune stimuli. Zídek, Z., Franková, D., Holý, A. Int. J. Immunopharmacol. (2000) [Pubmed]
  34. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Sheldon, J., Camino, N., Rodés, B., Bartholomeusz, A., Kuiper, M., Tacke, F., Núñez, M., Mauss, S., Lutz, T., Klausen, G., Locarnini, S., Soriano, V. Antivir. Ther. (Lond.) (2005) [Pubmed]
  35. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. Brenner, B.G., Oliveira, M., Doualla-Bell, F., Moisi, D.D., Ntemgwa, M., Frankel, F., Essex, M., Wainberg, M.A. AIDS (2006) [Pubmed]
  36. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. Mauss, S., Berger, F., Schmutz, G. AIDS (2005) [Pubmed]
  37. CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. Van Rompay, K.K., Singh, R.P., Pahar, B., Sodora, D.L., Wingfield, C., Lawson, J.R., Marthas, M.L., Bischofberger, N. J. Virol. (2004) [Pubmed]
  38. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. Miller, M.D., Margot, N., Lu, B., Zhong, L., Chen, S.S., Cheng, A., Wulfsohn, M. J. Infect. Dis. (2004) [Pubmed]
  39. Mechanism of active renal tubular efflux of tenofovir. Ray, A.S., Cihlar, T., Robinson, K.L., Tong, L., Vela, J.E., Fuller, M.D., Wieman, L.M., Eisenberg, E.J., Rhodes, G.R. Antimicrob. Agents Chemother. (2006) [Pubmed]
WikiGenes - Universities